Selpercatinib与Cabozantinib/Vandetanib患者报告耐受性比较:LIBRETTO-531随机对照试验二次分析
LIBRETTO-531随机3期试验二次分析显示,在RET突变晚期甲状腺髓样癌患者中,Selpercatinib组患者报告的高副作用负担时间比例显著低于对照组(8% vs 24%,p<0.0001)。Selpercatinib在健康相关生活质量各维度及严重腹泻、疲乏、味觉改变、食欲下降和手足综合征方面均表现更优。
要点
- Selpercatinib高副作用负担时间比例显著低于对照组(8% vs 24%)。
- Selpercatinib组HRQoL受损时间比例在躯体、角色、认知、情绪和社会功能维度均显著更低。
- Selpercatinib组严重腹泻、疲乏、味觉改变、食欲下降和手足综合征的时间比例显著更低。
核心结论
- 在RET突变晚期MTC患者中,Selpercatinib的患者报告耐受性优于Cabozantinib/Vandetanib对照。
- 该结果进一步支持Selpercatinib作为RET突变晚期MTC的一线治疗。
研究设计与样本
- LIBRETTO-531(NCT04211337)随机3期试验的二次分析,比较Selpercatinib与Vandetanib/Cabozantinib。
- 耐受性可评估人群N=242,其中Selpercatinib组n=161,对照组n=81(56例接受Cabozantinib,25例接受Vandetanib)。
- 患者每周自填FACT GP5条目「我被副作用困扰」,评分二分为低(0-2)和高(3-4)副作用负担。
主要发现
- Selpercatinib组高副作用负担时间比例显著低于对照组(8% vs 24%,p<0.0001)。
- Selpercatinib组HRQoL受损时间比例:躯体功能36% vs 52%,角色功能2% vs 11%,认知功能4% vs 8%,情绪功能6% vs 11%,社会功能2% vs 8%(均p<0.01)。
- Selpercatinib组严重腹泻时间比例5% vs 38%,疲乏6% vs 21%,味觉改变3% vs 15%,食欲下降2% vs 15%,手足综合征2% vs 9%(均p<0.001)。
- 两组PRO问卷基线后依从率一般大于80%。
关键数值与推荐
- 患者报告耐受性(PRT)以治疗期间高副作用负担时间比例(PTT)衡量。
- 比较PRT在双侧显著性水平0.05下检验,以疗效终点达到显著性为条件。
临床怎么用
- Selpercatinib较对照显著降低高副作用负担时间及HRQoL受损时间,支持其作为RET突变晚期MTC一线治疗选择。
- PRT可作为传统终点补充,用于未来随机对照试验中的监管与临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Progression-free survival (PFS) may not fully capture the impact of treatment on patients, especially in cancers with longer natural histories and thus, could be complemented by robust measures of patient-reported tolerability (PRT). We report the use of a novel, quantifiable PRT metric as a multiplicity-controlled endpoint to support regulatory and clinical decision-making for selpercatinib use. Comparative PRT was assessed in LIBRETTO-531 (NCT04211337), a randomized phase 3 trial of selpercatinib versus vandetanib/cabozantinib (control) in advanced RET-mutant medullary thyroid cancer (MTC). Patients and Methods: Patients were self-administered the single Functional Assessment of Cancer Therapy item GP5: "I am bothered by side effects" weekly, and scores were dichotomized into "low" (0-2) and "high" (3-4) side-effect burden. PRT measured the proportion of time on treatment (PTT) with "high" side-effect burden for each patient. Comparative PRT was tested at a two-sided significance level of 0.05, conditional on achieving significance for efficacy endpoints. Complementary patient-reported outcomes included health-related quality of life (HRQoL) and symptomatic adverse events self-administered at baseline and at different intervals post-baseline during treatment period. Results: In the tolerability evaluable population (N = 242; selpercatinib n = 161 and control n = 81 [56 received cabozantinib, 25 received vandetanib]), patients on selpercatinib had significantly better PRT with lower PTT with "high side-effect burden" than control (8% vs. 24%, p < 0.0001). Post-baseline compliance rates for PRO questionnaires were generally greater than 80% in both treatment groups. Patients on selpercatinib reported significantly less PTT with HRQoL impairment across physical (36% vs. 52%), role (2% vs. 11%), cognitive (4% vs. 8%), emotional (6% vs. 11%), and social (2% vs. 8%) function (all p < 0.01); and significantly less PTT with severe diarrhea (5% vs. 38%), fatigue (6% vs. 21%), taste change (3% vs. 15%), decreased appetite (2% vs. 15%), and hand-foot syndrome (2% vs. 9%) (all p < 0.001). Conclusion: This study demonstrated superior PRT for selpercatinib compared with control in patients with RET-mutant MTC, further supporting selpercatinib use as the first-line treatment for patients with advanced RET-mutant MTC. Comparative PRT deserves further adoption as a complement to traditional endpoints in future randomized-controlled trials.
引用
- Elisei R, Wirth LJ, Capdevila J, et al. Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET-Mutant Medullary Thyroid Cancer. Thyroid. 2025. PMID: 40828665. doi:10.1177/10507256251367352
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。